-11h 40m
5/21
Quarterly Report for Quarter Ending March 31, 2025 (Form 10-Q)
5/15
Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M
5/12
Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream
4/16
Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements
4/11
Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements
4/9
Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K)
4/3
Amendment to Current Report (Form 8-K/A)
4/3
Late Filing Notice (Form NT 10-K)
3/31